NCT Number: NCT02545257
The objective of this randomized controlled trial is to develop a coordinated, multiprofessional medication management model for home-dwelling aged in primary care and to study the effectiveness of this model. The main hypothesis is that the new model helps to identify aged people having potential risks with their medications and thus allows solving these risks.
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Not applicable
1st Pharmacy of Lohja, Lohja, Finland
The demand for long-term home health care services is increasing due the demographic and societal developments. Aged people needing home care are increasingly older, have many chronic diseases and use multiple medicines and thus, are at high risk for drug-related problems (DRPs). In Finland, national and local healthcare and aged care strategies target to allowing aged people (over 65 years) living in their own homes as long as possible. This minimizes the costs of institutionalized care and also targets to add the quality of life of aged people. New approaches and service models are needed to meet these challenges.
The present study focuses on the development of a coordinated medication management model which aims to ensure the safe medication practises for home-dwelling aged in primary care. In the previous parts of this study project were developed a model for comprehensive medication review process (CMR) and a Drug-Related Problem Risk Assessment Tool. The present study uses a multistage intervention in which medications are reviewed (prescription review) in a community pharmacy using the SFINX-database to identify clinically significant drug-drug interactions and the Salko-database which identifies potentially inappropriate medications for aged people. In the next stage practical nurses use the Drug-Related Problem Risk Assessment Tool to identify potential risks. The following stages are based on the results from the risk assessment tool. Potential options are, e.g.,physician consultation, more frequent home care visits, counselling given by the community pharmacy or comprehensive medication review (CMR). The CMR process is only targeted to a limited group of study participants with clinically significant DRP who probably will benefit from more comprehensive CMR.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Stage I: a prescription review conducted by community pharmacists Stage II: practical nurse-administered Drug-related Problem Risk Assessment Tool Stage III: Required health care action based on the result of the DRP -Risk Assessment Tool
Time frame: Change from baseline at 12 and 24 months
Time frame: Change from baseline at 12 and 24 months
Cognitive ability
Time frame: Change from baseline at 12 and 24 months
Time frame: Change from baseline at 12 and 24 months
Time frame: Change from baseline at 12 and 24 months
Time frame: Change from baseline at 12 and 24 months
Time frame: Change from baseline at 12 and 24 months
Time frame: Change from baseline at 12 and 24 months
Time frame: Change from baseline at 12 and 24 months
PIMs are identified with prescription review using SFINX database (clinically significant drug-drug interactions) and Salko database (e.g., for identifying potentially inappropriate medicines for the aged, anticholinergic and serotonergic load).
Time frame: at 12 and 24 months from baseline
Number of visits (previous 3 months)
Time frame: at 12 and 24 months from baseline
Number of hospital days (previous 3 months)
Time frame: at 12 and 24 months from baseline
Services delivered to home (previous 3 months)
University of Helsinki
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07027722
Antimalarials, Artemisinins
Saint-Denis, France
View Trial DetailsNCT02780622
Drug Therapy, Combination
Surrey, United Kingdom
View Trial DetailsNCT00294294
Body Temperature Changes, Drug Therapy, Combination
View Trial DetailsNCT03903484
Frailty, Inappropriate Prescribing
Halifax, Nova Scotia (NS), Canada
View Trial Details